'Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists.'

https://www.nejm.org/doi/full/10.1056/NEJMoa2302392?query=featured_home